Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RVMD vs AKRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RVMD Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 1–6 Matrix Metrics)

RVMD Overall Winner 6-Pillar Tally: RVMD 3 – 1 AKRO (2 Tie) Matrix Metrics: RVMD 1 – 6 AKRO

As of Nov 20, 2026, Revolution Medicines, Inc. (RVMD) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 1–6 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). RVMD carries a Unified Composite Score of 57.7/100 (HOLD) at $161.20 (N/M Forward P/E, -853.0% operating margin), whereas AKRO carries 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. RVMD 57.7/100 HOLD), RVMD captures the overall institutional head-to-head verdict (1–6 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-853.0% vs. 0.0% operating margin) and revenue trajectory (-95.2% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: RVMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.6); meanwhile AKRO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RVMD vs AKRO
RVMD NASDAQ Head-to-Head Winner
Revolution Medicines, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$161.20
+1.11% 1D
Market Cap $34.5B
TTM Revenue $198M
Forward P/E N/M
Beta / 30D Vol 1.35β · 61% Vol
Unified Composite Score
57.7 / 100 HOLD
Tech 62.0 Fund 64.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.7%), weak momentum, RSI 36
RSI-14: 35.6 · SMA20: $181.25 · SMA50: $190.02
AKRO NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.90β · 2% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 67
RSI-14: 67.3 · SMA20: $54.36 · SMA50: $52.91

6-Pillar Scorecard Institutional Category Breakdown (RVMD 3 – 1 AKRO)

Columns: Metric · RVMD · AKRO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale RVMD
Revenue Growth (YoY) -95.2% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $198M N/A
Market Cap $34.5B $4.5B
3. Profitability & Quality AKRO
Gross Margin N/A N/A
Operating Margin -853.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -93.6% -34.5%
4. Balance Sheet & Cash Flow RVMD
Cash Generation (TTM) -$1.44B N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $23M Net Debt (0.27x D/E) $11.95 Book/Sh · -34.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RVMD
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 56.9% (26th %ile) 7.3% (30th %ile)
Put/Call OI Skew 0.43x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Pharmaceutical Preparations Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RVMD (1) vs AKRO (6)
Institutional Metric RVMD AKRO Criterion Row Edge
Market Capitalization
Scale
$34.5B $4.5B Larger Scale RVMD
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-95.2% +0.0% Higher Growth AKRO
Operating Margin (TTM)
Profitability
-853.0% 0.0% Higher Margin AKRO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-93.6% -34.5% Higher ROE AKRO
52-Week Range Position
Momentum
59% ($70–$224) 90% ($21–$58) Stronger Trend AKRO
Beta / 30D Volatility
Risk Regime
1.35β · 61% Vol 0.90β · 2% Vol Lower Realized Risk AKRO
Unified Institutional Score
Composite Signal
57.7 / 100 (HOLD) 60.0 / 100 (BUY) Higher Composite AKRO
Trailing 12M Revenue (USD)
Operating Scale
$198M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.44B ($23M Net Debt (0.27x D/E)) N/A ($11.95 Book/Sh · -34.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RVMD +12.94 pp
RVMD: +13.51% · AKRO: +0.57%
3M Horizon RVMD +12.94 pp
RVMD: +13.51% · AKRO: +0.57%
6M Horizon RVMD +12.94 pp
RVMD: +13.51% · AKRO: +0.57%
1Y Horizon RVMD +12.94 pp
RVMD: +13.51% · AKRO: +0.57%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RVMD vs AKRO. Trailing 12-month operating profitability (RVMD -853.0% vs AKRO 0.0%) and valuation multiples (RVMD N/M vs AKRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

RVMD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$198M
Gross MarginN/A
Op. Margin-853.0%
ROE / Fwd P/E-93.6% · N/M
AKRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RVMD CONSOLIDATION
102d in phase · OBV DISTRIBUTION
Current IV 56.9%
IV Percentile 26th %ile
Put/Call OI Skew 0.43x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact RVMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AKRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 7.3%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $166.87 · IV 53.6%

RVMD Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($16,687)

Compare $16,687 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 53.6% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $170 / $185 Bull Call Spread

Buy 1x $170C · Sell 1x $185C · 32d

Net Entry $450 Debit
T+5d @ +5% Move +$167 (+37%)
Max Risk / Buffer $450 Capped
5d Edge & Liquidity 0.9x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $155 / $145 Bull Put Spread

Sell 1x $155P · Buy 1x $145P · 32d

Net Entry $235 Credit
Max Credit / Yield +$235 (+30.7% RoM)
Max Risk / Buffer -8.5% Cushion ($765 Mgn)
5d Edge & Liquidity 71% PoP · Liq B
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $150P / $170-$190C Seagull

Sell 1x $150P · Buy 1x $170/$190C · 32d

Net Entry $175 Debit
T+5d @ +5% Move +$417 (+19.1% RoM)
Max Risk / Buffer -10.1% Put Cushion ($2,180 Mgn)
5d Edge & Liquidity 0.9x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RVMD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $34.5B market capitalization and -853.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AKRO Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RVMD vs AKRO Key Questions & Quantitative Answers

As of Nov 20, 2026, Revolution Medicines, Inc. (RVMD) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 1–6 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). RVMD carries a Unified Composite Score of 57.7/100 (HOLD) at $161.20 (N/M Forward P/E, -853.0% operating margin), whereas AKRO carries 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. RVMD 57.7/100 HOLD), RVMD captures the overall institutional head-to-head verdict (1–6 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-853.0% vs. 0.0% operating margin) and revenue trajectory (-95.2% vs. +0.0% YoY). Technical & Structure Timing Caution: RVMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.6); meanwhile AKRO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RVMD leads the Growth & Scale pillar: RVMD posts -95.2% YoY revenue growth and +0.0% YoY earnings growth on $198M TTM revenue (N/A gross margin, -853.0% operating margin), compared with AKRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, RVMD generates $198M in USD-normalized revenue versus N/A for AKRO. In operating R&D and SG&A reinvestment, RVMD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKRO.

RVMD and AKRO trade at balanced relative valuation multiples. RVMD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RVMD (-93.6% ROE) versus AKRO (-34.5% ROE) capital efficiency.

In options market volatility and institutional positioning, RVMD carries 56.9% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.43x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.35β · 61% Vol realized risk). By comparison, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.